Low levels of vasoactive intestinal peptide are associated with Chagas disease cardiomyopathy

Human Immunology

Volumn 74, Issue 10, 2013, Pages 1375-1381

  Corrêa, Marielle Valério ^a   da Costa Rocha, Manoel Otávio ^a   de Sousa, Giovane Rodrigo ^a   do Carmo Pereira Nunes, Maria ^a   Gollob, Kenneth J ^b,c   Dutra, Walderez O ^a,c   da Silva Menezes, Cristiane Alves ^d  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b Santa Casa Hospital   (Brazil)

^c National Institute for Science and Technology in Tropical Diseases   (Brazil)

^d FEDERAL UNIVERSITY OF OURO PRETO   (Brazil)

Author keywords

LVDD; LVEF; VIP

Indexed keywords

VASOACTIVE INTESTINAL POLYPEPTIDE; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR 1; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR 2;

ADULT; AGED; ARTICLE; CHAGAS DISEASE; CROSS-SECTIONAL STUDY; DNA POLYMORPHISM; FEMALE; GENE FREQUENCY; HEART FUNCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; TRYPANOSOMA CRUZI;

LEFT VENTRICULAR DIASTOLIC DIAMETER; LEFT VENTRICULAR EJECTION FRACTION; LVDD; LVEF; VASOACTIVE INTESTINAL PEPTIDE; VIP;

ADULT; AGED; ALLELES; BRAZIL; CHAGAS CARDIOMYOPATHY; CROSS-SECTIONAL STUDIES; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; MALE; MIDDLE AGED; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, VASOACTIVE INTESTINAL PEPTIDE, TYPE II; RECEPTORS, VASOACTIVE INTESTINAL POLYPEPTIDE, TYPE I; VASOACTIVE INTESTINAL PEPTIDE;

EID: 84883818814     PISSN: 01988859     EISSN: 18791166     Source Type: Journal    
DOI: 10.1016/j.humimm.2013.06.028     Document Type: Article

References (36)

1. Nascimento B.R., Araújo C.G., Rocha M.O., et al. The prognostic significance of electrocardiographic changes in Chagas disease. J Electrocardiol 2012, 45(1):43-48. Epub 2011 Jun 24.
2. Dutra W.O., Menezes C.A., Villani F.N., et al. Cellular and genetic mechanisms involved in the generation of protective and pathogenic immune responses in human Chagas disease. Mem Inst Oswaldo Cruz 2009, 104(Suppl 1):208-218.
3. Prasse A., Zissel G., Lützen N., et al. Inhaled vasoactive intestinal peptide exerts immunoregulatory effects in sarcoidosis. Am J Respir Crit Care Med 2010 Aug 15, 182(4):540-548.
4. Pozo D., Gonzalez-Rey E., Chorny A., Anderson P., Varela N., Delgado M. Tuning immune tolerance with vasoactive intestinal peptide: a new therapeutic approach for immune disorders. Peptides 2007, 28(9):1833-1846.
5. Gonzalez-Rey E., Fernandez-Martin A., Chorny A., Delgado M. Vasoactive intestinal peptide induces CD4+CD25+ regulatory T cells with therapeutic effect on collagen-induced arthritis. Arthritis Rheum 2006, 54:864-876.
6. Delgado M., Pozo D., Ganea D. The significance of vasoactive intestinal peptide in immunomodulation. Pharmacol Rev 2004, 56:249-290.
7. Gonzalez-Rey E., Chorny A., Delgado M. Regulation of immune tolerance by anti-inflammatory neuropeptides. Nat Rev Immunol 2007, 7:52-63.
8. Juarranz Y., Gutierrez-Canas I., Santiago B., Carrion M., Pablos J.L., Gomariz R.P. Differential expression of vasoactive intestinal peptide and its functional receptors in human osteoarthritic and rheumatoid synovial fibroblasts. Arthritis Rheum 2008, 58:1086-1095.
9. Delgado M., Ganea D. Vasoactive intestinal peptide: a neuropeptide with pleiotropic immune functions. Amino Acids 2011, 3:4-5.
10. Sun W., Hong J., Zang Y.C., Liu X., Zhang J.Z. Altered expression of vasoactive intestinal peptide receptors in T lymphocytes and aberrant Th1 immunity in multiple sclerosis. Int Immunol 2006, 18:1691-1700.
11. Bangale Y., Karle S., Planque S., et al. VIPase autoantibodies in Fasd effective mice and patients with autoimmune disease. FASEB J 2003, 17:628-635.
12. Dutra W.O., Gollob K.J. Current concepts in immunoregulation and pathology of human Chagas disease. Curr Opin Infect Dis 2008, 21:287-292.
13. Boom R., Sol C.J., Salimans M.M., Jansen C.L., Wertheim-van Dillen P.M., van der Noordaa J. Rapid and simple method for purification of nucleic acids. J Clin Microbiol 1990 Mar, 28(3):495-503.
14. Moreira P.R., de Sa A.R., Xavier G.M., et al. A functional interleukin-1 beta gene polymorphism is associated with chronic periodontitis in a sample of brazilian individuals. J Periodontal Res 2005, 40:306-311.
15. Ribeiro A.L., Nunes M.P., Teixeira M.M., Rocha M.O. Diagnosis and management of Chagas disease and cardiomyopathy. Nat Rev Cardiol 2012 Oct, 9(10):576-589.
16. Andrade Z.A., Lopes E.A. A histochemical study of experimental Chagas' disease. Rev Inst Med Trop São Paulo. 1963, 5:236-242.
17. Delgado M., Robledo G., Rueda B., et al. Genetic association of vasoactive intestinal peptide receptor with rheumatoid arthritis: altered expression and signal in immune cells. Arthrities Rheum 2008, 58(4):1010-1019.
18. da Silveira A.B., D'Avila Reis D., de Oliveira E.C., et al. Neurochemical coding of the enteric nervous system in chagasic patients with megacolon. Dig Dis Sci 2007 Oct, 52(10):2877-2883.
19. Kierszenbaum F. Where do we stand on the autoimmunity hypothesis of Chagas disease?. Trends Parasitol 2005, 21:513-516.
20. Scherr M., Eder M. Gene silencing by small regulatory RNAs in mammalian cells. Cell Cycle 2007, 6:444-449.
21. Behm-Ansmant I., Rehwinkel J., Izaurralde E. MicroRNAs silence gene expression by repressing protein expression and/or by promoting mRNA decay. Cold Spring Harb Symp Quant Bio 2006, 71:523-530.
22. Voice J.K., Dorsam G., Lee H., Kong Y., Goetzl E.J. Allergic diathesis in transgenic mice with constitutive T cell expression of inducible vasoactive intestinal peptide receptor. FASEB J 2001, 15:2489-2496.
23. Goetzl E.J., Voice J.K., Shen S., et al. Enhanced delayed-type hypersensitivity and diminished immediate- type hypersensitivity in mice lacking the inducible VPAC2 receptor for vasoactive intestinal peptide. Proc Natl Acad Sci USA 2001, 98:13854-13859.
24. Voice J., Grinninger C., Kong Y., Bangale Y., Paul S., Goetzl E.J. Roles of vasoactive intestinal peptide (VIP) in the expression of different immune phenotypes by wild-type mice and T cell targeted type II VIP receptor transgenic mice. J Immunol 2003, 170:308-314.
25. Smalley S.G., Barrow P.A., Foster N. Immunomodulation of innate immune responses by vasoactive intestinal peptide (VIP): its therapeutic potential in inflammatory disease. Clin Exp Immunol 2009 Aug, 157(2):225-234.
26. Delgado M., Ganea D. Vasoactive intestinal peptide and pituitary adenylate cyclase activating polypeptide inhibit expression of Fas ligand in activated T lymphocytes by regulating c-Myc, NFkB, NF-AT, and early growth factors 2/3. J Immunol 2001, 166:1028-1040.
27. Yang X.-J., Ogyzko V.V., Nishikawa J., Howard B.H., Nakatani Y. A p300/CBP-associated factor that competes with the adenoviraloncoprotein E1A. Nature 1996, 382:319-324.
28. Fiuza J.A., Fujiwara R.T., Gomes J.A., Rocha M.O., Chaves A.T., de Araújo F.F., et al. Profile of central and effector memory T cells in the progression of chronic human Chagas disease. PLoS Negl Trop Dis 2009 Sep 9, 3(9):4-5.
29. Souza P.E., Rocha M.O., Menezes C.A., Coelho J.S., Chaves A.C., Gollob K.J., et al. Trypanosoma cruzi infection induces differential modulation of costimulatory molecules and cytokines by monocytes and T cells from patients with indeterminate and cardiac Chagas' disease. Infect Immun 2007, 75(4):1886-1894. Epub 2007 Feb 5.
30. Araujo F.F., Gomes J.A., Rocha M.O., Williams-Blangero S., Pinheiro V.M., et al. Potential role of CD4+CD25HIGH regulatory T cells in morbidity in Chagas disease. Front Biosci 2007, 12:2797-2806.
31. Gomes J.A., Bahia-Oliveira L.M., Rocha M.O., Busek S.C., Teixeira M.M., et al. Type 1 chemokine receptor expression in Chagas' disease correlates with morbidity in cardiac patients. Infect Immun 2005, 73:7960-7966.
32. Gomes J.A., Bahia-Oliveira L.M., Rocha M.O., Martins-Filho O.A., Gazzinelli G., et al. Evidence that development of severe cardiomyopathy in human Chagas' disease is due to a Th1-specific immune response. Infect Immun 2003, 71:1185-1193.
33. Menezes C.A., Rocha M.O., Souza P.E., Chaves A.C., Gollob K.J., Dutra W.O. Phenotypic and functional characteristics of CD28+ and CD28- cells from chagasic patients: distinct repertoire and cytokine expression. Clin Exp Immunol 2004 Jul, 137(1):129-138.
34. Moreira M.D., Brehmer A., de Oliveira E.C., Neto S.G., Luquetti A.O., Bueno L.L., et al. Regenerative process evaluation of neuronal subclasses in chagasic patients with megacolon. Hum Immunol 2013, 74(2):181-188.
35. da Silveira A.B., Freitas M.A., de Oliveira E.C., Neto S.G., Luquetti A.O., Furness J.B., Reis D.D. Substance P and NK1 receptor expression in the enteric nervous system is related to the development of chagasic megacolon. Trans R Soc Trop Med Hyg 2008, 102(11):1154-1156.
36. Nascimento R.D., Martins P.R., De Souza Lisboa A., Adad S.J., Morais da Silveira A.B., Reis D.D. An imbalance between substance P and vasoactive intestinal polypeptide might contribute to the immunopathology of megaesophagus after Trypanosoma cruzi infection. Hum Pathol 2013, 44(2):269-276.